156605-95-7 Usage
Uses
Used in Pharmaceutical Industry:
1-Bromo-4-ethoxy-2-(trifluoromethyl)benzene is used as a chemical intermediate for the synthesis of various pharmaceuticals. Its unique structure allows for the development of new drugs with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical sector, 1-Bromo-4-ethoxy-2-(trifluoromethyl)benzene serves as a precursor in the production of agrochemicals, contributing to the development of effective pesticides and other agricultural chemicals.
Used in Specialty Chemicals Production:
1-Bromo-4-ethoxy-2-(trifluoromethyl)benzene is utilized as a building block in the creation of specialty chemicals, which are high-value chemicals used in specific applications due to their unique properties.
Used in Organic Compounds Synthesis:
1-Bromo-4-ethoxy-2-(trifluoromethyl)benzene is employed as a key component in the synthesis of other organic compounds, expanding the range of chemical products available for various industries.
Check Digit Verification of cas no
The CAS Registry Mumber 156605-95-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,5,6,6,0 and 5 respectively; the second part has 2 digits, 9 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 156605-95:
(8*1)+(7*5)+(6*6)+(5*6)+(4*0)+(3*5)+(2*9)+(1*5)=147
147 % 10 = 7
So 156605-95-7 is a valid CAS Registry Number.
156605-95-7Relevant articles and documents
6-Phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives
-
Page/Page column 8-9, (2010/11/28)
The present invention relates to 6-phenyl-1H-imidazo[4,5-c]pyridine-4-carbonitrile derivatives having the general Formula I wherein each of the substituents is given the definition as set forth in the specification and claims, pharmaceutical compositions comprising the same as well as to the use of these derivatives for the preparation of a medicament for the treatment of cathepsin S and/or cathepsin K related diseases such as osteoporosis, atherosclerosis, inflammation and immune disorders, such as rheumatoid arthritis, and chronic pain, such as neuropathic pain.
Liquid crystalline compound, liquid crystal composition and their polymers
-
, (2008/06/13)
The present invention provides a compound represented by formula (1) defined in the specification and a liquid crystal composition comprising the compound. The invention further provides a polymer obtained by polymerization of compound or composition abov
